Allergy Therapeutics PLC Expansion of Clinical Development and R&D teams (2846Q)
11 September 2017 - 4:00PM
UK Regulatory
TIDMAGY
RNS Number : 2846Q
Allergy Therapeutics PLC
11 September 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Expansion of Clinical Development and R&D teams
- Key appointments reflect Group's commitment to EU and US
strategy for product development -
11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, today announces new senior appointments and expansion of
the R&D and clinical team in line with the Group's growth plans
at the Group's UK headquarters in Worthing. These appointments are
aimed at broadening the clinical development team in order to
facilitate continued progress of the pipeline and clinical
development programmes, in addition to continuing to prepare for US
market entry.
The Group has underlined its commitment to clinical excellence
by appointing Pieter-Jan de Kam as Clinical Director effective
immediately. Pieter-Jan de Kam joins the Group from HAL Allergy in
The Netherlands where he was responsible for clinical development,
with recent successes including European and US studies for pollen
and house dust mites. Prior to that, Pieter-Jan worked across
Europe, in the US and in Singapore in various roles including
Director of Clinical Research at Merck Sharp & Dohme.
In addition to the appointment of Pieter-Jan, the Group has
recruited Simon Piggott as Head of Clinical Science. Simon will be
responsible for the delivery of Allergy Therapeutics' robust
clinical strategy to facilitate progression of the Group's broad
pipeline and innovative technologies, working with both the
established product development teams and clinical operations
departments. Simon has significant experience including successful
respiratory development programs through Phase I to IV having
previously worked as Global Scientific Director at GSK and
Associate Director at Quintiles and Vertex.
As part of the Group's continued investment in its R&D
function, Tim Higenbottam has been appointed to the position of
Senior Pharmaceutical Physician and will focus on the US regulatory
process, a key part of the Group's three-pillar growth strategy.
The R&D team which is led by Murray Skinner, Chief Scientific
Officer, has doubled the size of its headcount since 2016.
Murray Skinner, Chief Scientific Officer of Allergy
Therapeutics, commented: "We are delighted to welcome Pieter-Jan
and Simon to the Allergy Therapeutics team. Their vast experience
and expert knowledge is ideally focussed to promote continued
innovation and help us bring new and convenient products for
patients into the allergy immunotherapy market."
Pieter-Jan de Kam, new Clinical Director at Allergy
Therapeutics, stated: "This is a company with a long history in
allergen immunotherapy, an excellent pipeline of innovative allergy
products and a focus on addressing the causes of allergy to help
patients with their allergy. I am very excited to be able to join
the Company at such a crucial time in its development and look
forward to leading the clinical team to continued successes."
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDDMGGLKRLGNZM
(END) Dow Jones Newswires
September 11, 2017 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024